Evaluating Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: Insights From the ABLE-22 Trial

Sia Daneshmand, MD, of the University of Southern California, discusses the ongoing ABLE-22 trial, which evaluates nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. In this interview, Dr. Daneshmand explores whether adding chemotherapy or immunotherapy to nadofaragene firadenovec can improve outcomes and extend response duration. The discussion also covers the trial’s approach to reinduction, the rationale for combining different mechanisms of action, and the potential impact on bladder preservation rates.